Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells

Human Antibodies

Volumn 21, Issue 3-4, 2012, Pages 49-56

  Kouchakzadeh, Hasan ^a   Shojaosadati, Seyed Abbas ^a   Mohammadnejad, Javad ^b   Paknejad, Malihe ^c   Rasaee, Mohammad Javad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 Fluorouracil; BSA nanoparticle; MCF7 cell lines; MUC1; PR81 mAb

Indexed keywords

ANTIBODY CONJUGATE; BOVINE SERUM ALBUMIN; FLUOROURACIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MUC1; NANOCARRIER; PR81 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRAIN MCF 7; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; TARGET CELL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; MUCIN-1; NANOPARTICLES; NEOPLASM PROTEINS; SERUM ALBUMIN, BOVINE;

EID: 84876209954     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-2012-0261     Document Type: Article

References (56)

1. Y. Bae, T.A. Diezi, A. Zhao and G.S. Kwon, Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents, J Control Release 122 (2007), 324-30.
2. A.I. Minchinton and I.F. Tannok, Drug penetration in solid tumours, Nat Rev Cancer 6 (2006), 583-92.
3. M.R. Kano, Y. Bae, C. Lwata, Y. Morishita, M. Yashiro, M. Oka et al., Improvement of cancer-targeting therapy, using nanocarriers for in tractable solid tumors by inhibition of TGFbeta signaling, P Natl Acad Sci USA 104 (2007), 3460-65.
4. F.Q. Hu, P. Meng, Y.Q. Dai, Y.Z. Du, J. You, X.H. Wei et al., PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy, Eur J Pharm Biopharm 70 (2008), 749-57.
5. A. Jain and S.K. Jain, In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors, Eur J Pharm Sci 35 (2008), 404-16.
6. P. Couvreur and C. Vauthier, Nanotechnology: Intelligent design to treat complex disease, Pharm Res 23 (2006), 1417-50.
7. S. Parveen, R. Misra and S.K. Sahoo, Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging, Nanomed-Nanotechnol 8 (2012), 147-166.
8. A.H. Faraji and P. Wipf, Nanoparticles in cellular drug delivery, Bioorgan med chem 17 (2009), 2950-2962.
9. M.G.Anhorn, S.Wagner, J. Kreuter, K. Langer and H. Briesen, Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles, Bioconjugate Chem 19 (2008), 2321-31.
10. A. Maghsoudi, S.A. Shojaosadati and E. Vasheghani Farahani, 5-Fluorouracil-loaded BSA nanopaticles: Formulation optimization and in vitro release study, AAPS Pharmscitech 9 (2008), 1092-96.
11. B.G. Muller, H. Leuenberger and T. Kissel, Albumin nanospheres as carriers for passive drug targeting: An optimizedmanufacturing technique, Pharm Res 13 (1996), 32-37.
12. G.V. Patil, Biopolymer albumin for diagnosis and in drug delivery, Drug Develop Res 58 (2003), 219-47.
13. A.O. Elzoghby,W.M. Samy and N.A. Elgindy,Albumin-based nanoparticles as potential controlled release drug delivery systems, J Control Release 157 (2012), 168-182.
14. M. Merodio, A. Arnedo, M.J. Renedo and J.M. Irache, Ganciclovir-loaded albumin nanoparticles: Characterization and in vitro release, Eur J Pharm Sci 12 (2001), 251-59.
15. M. Merodio, J.M. Irache, F.Valamanesh andM.Mirshahi, Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticle after intraviral injection in rats, Biomaterials 23 (2002), 1587-59.
16. W. Lin, M.C. Garnett, S.S. Davis, E. Schacht, P. Ferruti and L. Illum, Preparation and characterization of rose Bengal-loaded surface-modified albumin nanoparticles, J Control Release 71 (2001), 117-26.
17. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. Von Briesen and D. Schubert, Optimization of the preparation process for human serum albumin (HSA) nanoparticles, Int J Pharm 257 (2003), 169-80.
18. S.Wagner, F. Rothweiler, M.G. Anhorn, D. Sauer, I. Riemann, E.C.Weiss, A. Kasten-Globa, M. Michaelis, J. Cindrich Jr, D. Schwartz, J. Kreuter, H.V. Briesen and K. Langer, Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles, Biomaterials 31 (2010), 2388-2398.
19. H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter and K. Langer, Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells, J Drug Target 12 (2004), 461-71.
20. S. Dreis, F. Rothweiler, M. Michaelis, Jr., J. Cinatl, J. Kreuter and K. Langer, Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles, Int J Pharm 341 (2007), 207-14.
21. C. Weber, S. Reiss and K. Langer, Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups, Int J Pharm 211 (2000), 67-78.
22. V.P. Torchilin, Passive and active drug targeting: Drug delivery to tumors as an example, Handbook of experimental pharmacology, Springer-Verlag BerlinHeidelberg 197 (2010), 3-53.
23. S. Kim, J. Kim, O. Jeon, I.C. Kwon and K. Park, Engineered polymers for advanced drug delivery, Eur J Pharm Biopharm 71 (2009), 420-30.
24. T. Lammers, F. Kissling, W.E. Hennink and G. Storm, Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress, J Control Release 161 (2012), 175-187.
25. F. Danhier, O. Feron and V. Preat, To exploit the tumor microenvironment: Passive and active targeting of nanocarriers for anti-cancer drug delivery, J Controll Release 148 (2010), 135-146.
26. O. Koo, I. Rubinstein and H. Onyuksel, Role of nanotechnology in targeted drug delivery and imaging: A concise review, Nanomed-Nanotechnol 1 (2005), 193-212.
27. C.S. Cho, K.Y. Cho, I.K. Park, S.H. Kim, T. Sasagawa and M.Uchiyama, Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly (L-Lactic acid) nanoparticles coated with galactose-carrying polysturene, J Control Release 77 (2001), 7-15.
28. G.J. Russel-Jones, L. Arthur and H. Walker, Vitamin B12- mediated transport of nanoparticles across caco-2 cells, Int J Pharm 179 (1999), 247-55.
29. B. Stella, S. Arpicco, M.T. Peracchia, D. Desmaele, J. Hoebeke and M. Renoir, Design of folic acid-conjugated nanoparticles for drug targeting, J Pharm Sci 89 (2000), 1452-64.
30. S. Choi and J. Kim, Design of surface-modified poly (D,LLactide- Co-Glycolide) nanoparticles for targeted drug delivery to bone, J Control Release 122 (2007), 24-30.
31. A.V. Kabanov, V.P. Chekhonin, V. Alakhov, E.V. Batrakova, A.S. Lebedev and N.S. Melik-Nubarov, The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles: Micelles as microcontainers for drug targeting, FEBS Lett, 258 (1989), 343-45.
32. V.P. Torchilin, A.N. Lukyanov, Z. Gao and B. Papahadjopoulos- Sternberg, Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs, P Natl Acad Sci USA 100 (2003), 6039-44.
33. P. Kocbek, N. Obermajer, M. Cegner, J. Kos and J. Kristl, Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, J Control Release 120 (2007), 18-26.
34. H. Shmeeda, D. Tzemach, L. Mak and A. Gabizon, HER2- targeted pegylated liposomal doxorubicin: Retention of targetspecific binding and cytotoxicity after in vivo passage, J Control Release 136 (2009), 155-60.
35. H. Kouchakzadeh, S. A. Shojaosadati, A. Maghsoudi and E. Vasheghani Farahani, Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology, AAPS PharmSciTech 11(3) (2010), 1206-1211.
36. W. Lin, M.C. Garnett, E. Schacht, S.S. Davis and L. Illum, Preparation and in vitro characterization of HSA-mPEG nanoparticles, Int J Pharm 189 (1999), 161-70.
37. K. Langer, Peptide nanoparticles. In: C. Kumar, ed., Biological and Pharmaceutical nanomaterials, Wiley-VCH (2006), 145-184.
38. I. Brigger, C. Dubernet and P. Couvreur, Nanoparticles in cancer therapy and diagnosis, AdvDrugDeliver Rev 54 (2002), 631-51.
39. R.M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang and G. Storm, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticles, Nucleic Acids Res 32 (2004), e149.
40. I. Steinhauser, B. Spankuch, K. Strebhardt and K. Langer, Trastuzumab-modified nanoparticles: Optimization of preparation and uptake in cancer cells, Biomaterials 27 (2006), 4975-83.
41. I. Steinhauser, K. Langer, K. Strebhardt and B. Spankuch, Effect of trastuzumab-modified antisense oligonucleotideloaded human serum albumin nanoparticles prepared by heat denaturation, Biomaterials 29 (2008), 4022-28.
42. D.C. Bibby, J.E. Talmadge, M.K. Dalal, S.G. Kurz, K.M. Chytil and S.E. Barry, Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumorbearing mice, Int J Pharm 293 (2005), 281-90.
43. L. Nobs, F. Buchegger, R. Gurny and E. Allemann, Biodegradable nanoparticles for direct two-step tumor, immunotargeting Bioconjugate Chem 17 (2006), 139-45.
44. J. Taylor, J. Burchell, D.W. Miles and M. Dalziel, MUC1 and cancer, BBA-Mol Basis Dis 1455 (1999), 301-13.
45. R. Kokko, K. Holli and M. Hakan, CA 15.3 in the follow-up of localized breast cancer: A prospective study, Eur J Cancer 38 (2002), 1189-93.
46. M. Salouti, H. Rajabi, M.H. Babaei and M.J. Rasaee, Breast tumor targeting with 99mTC-HYNIC-PR81 complex as a new biologic radiopharmaceutical, Nucl Med Biol 35 (2008), 763-68.
47. F. Rahbarizadeh, M.J. Rasaee, M. Forouzandeh and A. Allameh, Overexpression of anti-MUC1 single-domain antibody fragments in the yeast, pichia pastorisMol Immunol 43 (2006), 420-35.
48. J. Schuhmacher, G. Klivenyi, S. Kaul, M. Henze, R. Matys and H. Hauser, Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET, Nucl Med Biol 28 (2001), 821-28.
49. J. Schuhmacher, S. Kaul, G. Klivenyi, H. Junkermann, A. Magener and M. Henze, Immunoscintigraphy with positron emission tomography: Gatlium-68 chelate imaging of breast cencer pretargeted with bispecific anti MUC1/anti-Ga chelate antibodies, Cancer Res 61 (2001), 3712-17.
50. J.T. Papadimitrious, J.M. Burchell, T. Plunkett, R. Graham, L. Correa, D. Miles and M. Smith, MUC1 and immunobiology of cancer, J Mammary Gland Biol 7 (2002), 209-21.
51. J.Mohammadnejad, M.J. Rasaee, M.H. Babaei, M. Paknejad, M.H. Zahir, M. Salouti, A. Bitarafan Rajabi and M.Mazidi, A new radiopharmaceutical compound (131IPR81) for radioimmunotherapy of breast cancer: Labeling of antibody and its quality control, Human Antibodies 19 (2010), 79-88.
52. J. Mohammadnejad, M.J. Rasaee, M.H. Babaei, M. Paknejad and Z.M. Hasan, Mojtaba Salouti, Mostafa Gandomkar, Keyvan Sadri, Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody againstMUC1: Comparison of direct and indirect radioiodination methods, Human Antibodies 19 (2010), 15-25.
53. M. Paknejad, M.J. Rasaee, F. Karami, S. Kashanian, M.A. Mohagheghi and K. Omidfar, Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin, Hybridoma Hybridom 22 (2003), 153-58.
54. J. Mohammadnejad, M.J. Rasaee, B. Saghafi, M. Rajabibazl, F. Rahbarizadeh and K. Omidfar, A new competitive enzyme linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer, J Immunoass Immunoch 27 (2006), 139-49.
55. F. Rahbarizadeh, M.J.Rasaee,M. Forouzandeh, A.A.Allameh and E. Sadroddiny, Production of novel recombinant singledomain antibodies against tandem repeat region of MUC1 mucin, Hybridoma Hybridom 23 (2004), 151-59.
56. G.T. Hermanson, Bioconjugation Technique. 2nd ed. (2008), Elsevier Inc, newyork.